Objectives: The effect of amino-bisphosphonates on osteoblastic lineage and its potential contribution to the pathogenesis of bisphosphonate-associated osteonecrosis of the jaw (BONJ) remain controversial. We assessed the effects of zoledronic acid (ZOL) on bone and vascular cells of the alveolar socket using a mouse model of BONJ. Material and Methods: Thirty-two mice were treated twice a week with either 100 μg/kg of ZOL or saline for 12 weeks. The first left maxillary molar was extracted at the third week. Alveolar sockets were assessed at both 3 weeks (intermediate) and 9 weeks (long-term) after molar extraction by semi-quantitative histomorphometry for empty lacunae, preosteoblasts (Osterix), osteoclasts (TRAP), and pericyte-li...
Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) is clinically characterized by the presence ...
Bisphosphonate (BP)-related osteonecrosis of the jaw, previously known as BRONJ, now referred to mor...
Patients on high-dose bisphosphonate and immunosuppressive therapy have an increased risk of bisphos...
Objectives: The effect of amino-bisphosphonates on osteoblastic lineage and its potential contributi...
Bisphosphonate-associated osteonecrosis of the jaw (BONJ) is a morbid bone disease linked to long-te...
Bisphosphonate-related osteonecrosis of the jaw is a pathological condition without effective establ...
Drug-induced osteonecrosis of the jaw (ONJ) is a detrimental intraoral lesion that often occurs afte...
Osteonecrosis of the jaws (ONJ) is a significant complication of antiresorptive medications, such as...
Objectives: Bisphosphonates are widely used to treat bone diseases such as osteoporosis. However, th...
Despite the efficacy of bisphosphonates (Bps) in management of skeletal diseases, they have been ass...
Bisphosphonates (BPs) have been used clinically for over 30 years to treat postmenopausal osteoporos...
Drug-induced osteonecrosis of the jaw (ONJ) is a detrimental intraoral lesion that often occurs afte...
Objective – The pathophysiology of osteonecrosis of the jaw (ONJ) is thought to be linked to suppre...
BACKGROUND: The aim of this study is to develop a rat model of bisphosphonates-related osteonecrosis...
Purpose: Factors contributing to osteonecrosis of the jaw with anti-remodeling drug treatment are un...
Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) is clinically characterized by the presence ...
Bisphosphonate (BP)-related osteonecrosis of the jaw, previously known as BRONJ, now referred to mor...
Patients on high-dose bisphosphonate and immunosuppressive therapy have an increased risk of bisphos...
Objectives: The effect of amino-bisphosphonates on osteoblastic lineage and its potential contributi...
Bisphosphonate-associated osteonecrosis of the jaw (BONJ) is a morbid bone disease linked to long-te...
Bisphosphonate-related osteonecrosis of the jaw is a pathological condition without effective establ...
Drug-induced osteonecrosis of the jaw (ONJ) is a detrimental intraoral lesion that often occurs afte...
Osteonecrosis of the jaws (ONJ) is a significant complication of antiresorptive medications, such as...
Objectives: Bisphosphonates are widely used to treat bone diseases such as osteoporosis. However, th...
Despite the efficacy of bisphosphonates (Bps) in management of skeletal diseases, they have been ass...
Bisphosphonates (BPs) have been used clinically for over 30 years to treat postmenopausal osteoporos...
Drug-induced osteonecrosis of the jaw (ONJ) is a detrimental intraoral lesion that often occurs afte...
Objective – The pathophysiology of osteonecrosis of the jaw (ONJ) is thought to be linked to suppre...
BACKGROUND: The aim of this study is to develop a rat model of bisphosphonates-related osteonecrosis...
Purpose: Factors contributing to osteonecrosis of the jaw with anti-remodeling drug treatment are un...
Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) is clinically characterized by the presence ...
Bisphosphonate (BP)-related osteonecrosis of the jaw, previously known as BRONJ, now referred to mor...
Patients on high-dose bisphosphonate and immunosuppressive therapy have an increased risk of bisphos...